WO2004096159A3 - Saposin c-dops: a novel anti-tumor agent - Google Patents
Saposin c-dops: a novel anti-tumor agent Download PDFInfo
- Publication number
- WO2004096159A3 WO2004096159A3 PCT/US2004/008020 US2004008020W WO2004096159A3 WO 2004096159 A3 WO2004096159 A3 WO 2004096159A3 US 2004008020 W US2004008020 W US 2004008020W WO 2004096159 A3 WO2004096159 A3 WO 2004096159A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- saposin
- dops
- tumor agent
- novel anti
- tumor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2522833A CA2522833C (en) | 2003-04-28 | 2004-03-17 | Saposin c-dops: a novel anti-tumor agent |
EP04760194.3A EP1635856B1 (en) | 2003-04-28 | 2004-03-17 | Saposin c-dops: a novel anti-tumor agent |
BRPI0409926 BRPI0409926A (en) | 2003-04-28 | 2004-03-17 | saposin c-dops: an antitumor agent |
AU2004233775A AU2004233775C1 (en) | 2003-04-28 | 2004-03-17 | Saposin C-dops: a novel anti-tumor agent |
ES04760194T ES2828094T3 (en) | 2003-04-28 | 2004-03-17 | Saponin C dops: a new antitumor agent |
JP2006507237A JP4762132B2 (en) | 2003-04-28 | 2004-03-17 | Saposin C-DOPS: Novel antitumor agent |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46616603P | 2003-04-28 | 2003-04-28 | |
US60/466,166 | 2003-04-28 | ||
US10/801,517 US7834147B2 (en) | 2003-04-28 | 2004-03-16 | Saposin C-DOPS: a novel anti-tumor agent |
US10/801,517 | 2004-03-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004096159A2 WO2004096159A2 (en) | 2004-11-11 |
WO2004096159A3 true WO2004096159A3 (en) | 2005-09-01 |
Family
ID=33423597
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/008020 WO2004096159A2 (en) | 2003-04-28 | 2004-03-17 | Saposin c-dops: a novel anti-tumor agent |
Country Status (8)
Country | Link |
---|---|
US (4) | US7834147B2 (en) |
EP (1) | EP1635856B1 (en) |
JP (1) | JP4762132B2 (en) |
AU (2) | AU2004233775C1 (en) |
BR (1) | BRPI0409926A (en) |
CA (2) | CA2522833C (en) |
ES (1) | ES2828094T3 (en) |
WO (1) | WO2004096159A2 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7834147B2 (en) * | 2003-04-28 | 2010-11-16 | Childrens Hospital Medical Center | Saposin C-DOPS: a novel anti-tumor agent |
WO2007127439A2 (en) * | 2006-04-28 | 2007-11-08 | Children's Hospital Medical Center | Compositions comprising fusogenic proteins or polypeptides derived from prosaposin for application in transmembrane drug delivery systems |
CA2666953A1 (en) * | 2006-10-20 | 2008-05-02 | Children's Hospital Medical Center | Spontaneous forming ellipsoidal phospholipid unilamellar vesicles |
AU2013203640B2 (en) * | 2007-06-22 | 2017-04-13 | Children's Medical Center Corporation | Methods and uses thereof of prosaposin |
EP3666284A1 (en) * | 2007-06-22 | 2020-06-17 | Children's Medical Center, Corp. | Methods and uses thereof of a fragment of saposin a |
CA2822026C (en) * | 2009-12-17 | 2018-06-12 | Children's Medical Center Corporation | Saposin-a derived peptides and uses thereof |
WO2012154825A1 (en) * | 2011-05-09 | 2012-11-15 | Thornton Sherry L | Method for imaging a site of arthritis in an animal |
AU2012358269B2 (en) | 2011-12-22 | 2017-11-02 | Children's Medical Center Corporation | Saposin-A derived peptides and uses thereof |
EP2919759A4 (en) * | 2012-11-14 | 2016-07-20 | Ohio State Innovation Foundation | Materials and methods useful for treating glioblastoma |
ES2608857T3 (en) | 2012-12-18 | 2017-04-17 | Salipro Biotech Ag | Salipro particles |
EP2971166B1 (en) | 2013-03-14 | 2021-05-19 | Children's Medical Center Corporation | Psap peptide for treating cd36 expressing cancers |
LT3043814T (en) | 2013-09-13 | 2021-02-25 | Salipro Biotech AB | Antigen and method for production thereof |
CA2943802A1 (en) | 2014-03-26 | 2015-10-01 | Children's Medical Center Corporation | Cyclic prosaposin peptides and uses thereof |
US20180169120A1 (en) * | 2016-11-21 | 2018-06-21 | Bexion Pharmaceuticals, Inc. | Combination therapy including sapc-dops for the treatment of pancreatic cancer |
EP3697387B1 (en) | 2017-10-16 | 2024-03-06 | University of Cincinnati | Combination of as1411 and sapc-dops for the treatment of glioblastoma multiforme |
WO2019079245A1 (en) | 2017-10-16 | 2019-04-25 | University Of Cincinnati | Combination therapy of fractionated radiation and sapc-dops for the treatment of tumors |
MX2020009829A (en) | 2018-03-23 | 2021-01-08 | Bexion Pharmaceuticals Inc | Saposin c pharmaceutical compositions and methods of treating cancer. |
WO2021183596A1 (en) * | 2020-03-10 | 2021-09-16 | University Of Cincinnati | Materials and methods for the treatment of gaucher disease |
WO2023174210A1 (en) | 2022-03-14 | 2023-09-21 | Laekna Limited | Combination treatment for cancer |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6271196B1 (en) * | 1996-03-05 | 2001-08-07 | Regents Of The University Of Ca | Methods of alleviating neuropathic pain using prosaposin-derived peptides |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2002A (en) * | 1841-03-12 | Tor and planter for plowing | ||
US2001A (en) * | 1841-03-12 | Sawmill | ||
US2003A (en) * | 1841-03-12 | Improvement in horizontal windivhlls | ||
NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4552811A (en) | 1983-07-26 | 1985-11-12 | Appleton Papers Inc. | Capsule manufacture |
US4588580B2 (en) | 1984-07-23 | 1999-02-16 | Alaz Corp | Transdermal administration of fentanyl and device therefor |
US4904475A (en) | 1985-05-03 | 1990-02-27 | Alza Corporation | Transdermal delivery of drugs from an aqueous reservoir |
GB8514665D0 (en) | 1985-06-11 | 1985-07-10 | Eroceltique Sa | Oral pharmaceutical composition |
US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
US4816258A (en) | 1987-02-26 | 1989-03-28 | Alza Corporation | Transdermal contraceptive formulations |
US4788062A (en) | 1987-02-26 | 1988-11-29 | Alza Corporation | Transdermal administration of progesterone, estradiol esters, and mixtures thereof |
JPS63250323A (en) * | 1987-04-03 | 1988-10-18 | Nichirei:Kk | Novel anticancer agent |
US4927408A (en) | 1988-10-03 | 1990-05-22 | Alza Corporation | Electrotransport transdermal system |
CA2025907A1 (en) * | 1989-09-21 | 1991-03-22 | Franklin D. Collins | Method of transporting compositions across the blood brain barrier |
MX9305070A (en) | 1992-08-21 | 1994-04-29 | Genentech Inc | PHARMACEUTICAL COMPOSITION CONTAINING AN LFA-1 ANTAGONIST FOR THE TREATMENT OF DISORDERS OR DISORDERS MEDIATED BY LFA-1 |
US5700909A (en) * | 1993-07-30 | 1997-12-23 | The Regents Of The University Of California | Prosaposin and cytokine-derived peptides |
EP0720852B1 (en) * | 1993-08-13 | 2000-11-22 | Seikagaku Corporation | Remedy for nervous diseases |
DE69534676T2 (en) * | 1994-02-08 | 2006-08-17 | Amgen Inc., Thousand Oaks | Oral administration of chemically modified proteins |
US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
DE19541284C2 (en) * | 1995-11-06 | 1998-09-24 | Kalden Joachim Robert Prof Dr | Immunomodulation method |
AU6041498A (en) * | 1997-02-04 | 1998-08-25 | Abbott Laboratories | Pain reducing parenteral liposome formulation |
JP2001524944A (en) * | 1997-03-05 | 2001-12-04 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | How to relieve neuropathic pain |
EP0971956A2 (en) * | 1997-03-24 | 2000-01-19 | Myelos Corporation | Synthetic saposin c-derived neurotrophic peptides |
AU772778B2 (en) * | 1998-07-13 | 2004-05-06 | University Of Southern California | Novel inhibitors of angiogenesis and tumor growth |
US20020177551A1 (en) | 2000-05-31 | 2002-11-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
US6872406B2 (en) | 2000-02-11 | 2005-03-29 | Children's Hospital Research Foundation | Fusogenic properties of saposin C and related proteins and polypeptides for application to transmembrane drug delivery systems |
AU2001249078A1 (en) | 2000-02-28 | 2001-09-12 | Millenium Pharmaceuticals, Inc. | 27411, a novel human pgp synthase |
WO2001064894A2 (en) | 2000-02-29 | 2001-09-07 | Millennium Pharmaceuticals, Inc. | Human phospholipid scramblase-like molecules and uses thereof |
US7166691B2 (en) | 2002-12-20 | 2007-01-23 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Saposin C and receptors as targets for treatment of benign and malignant disorders |
US7834147B2 (en) * | 2003-04-28 | 2010-11-16 | Childrens Hospital Medical Center | Saposin C-DOPS: a novel anti-tumor agent |
WO2007127439A2 (en) * | 2006-04-28 | 2007-11-08 | Children's Hospital Medical Center | Compositions comprising fusogenic proteins or polypeptides derived from prosaposin for application in transmembrane drug delivery systems |
CA2666953A1 (en) | 2006-10-20 | 2008-05-02 | Children's Hospital Medical Center | Spontaneous forming ellipsoidal phospholipid unilamellar vesicles |
US9274932B2 (en) | 2011-05-12 | 2016-03-01 | Webtrends, Inc. | Graphical-user-interface-based method and system for designing and configuring web-site testing and analysis |
-
2004
- 2004-03-16 US US10/801,517 patent/US7834147B2/en not_active Expired - Fee Related
- 2004-03-17 ES ES04760194T patent/ES2828094T3/en not_active Expired - Lifetime
- 2004-03-17 BR BRPI0409926 patent/BRPI0409926A/en not_active Application Discontinuation
- 2004-03-17 WO PCT/US2004/008020 patent/WO2004096159A2/en active Application Filing
- 2004-03-17 CA CA2522833A patent/CA2522833C/en not_active Expired - Lifetime
- 2004-03-17 JP JP2006507237A patent/JP4762132B2/en not_active Expired - Lifetime
- 2004-03-17 EP EP04760194.3A patent/EP1635856B1/en not_active Expired - Lifetime
- 2004-03-17 AU AU2004233775A patent/AU2004233775C1/en not_active Expired
- 2004-03-17 CA CA2911022A patent/CA2911022C/en not_active Expired - Lifetime
-
2008
- 2008-12-11 US US12/332,809 patent/US8937156B2/en not_active Expired - Fee Related
-
2010
- 2010-01-22 AU AU2010200264A patent/AU2010200264B2/en not_active Expired
-
2014
- 2014-12-10 US US14/566,501 patent/US10188698B2/en not_active Expired - Fee Related
-
2018
- 2018-12-19 US US16/226,468 patent/US20190192623A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6271196B1 (en) * | 1996-03-05 | 2001-08-07 | Regents Of The University Of Ca | Methods of alleviating neuropathic pain using prosaposin-derived peptides |
Also Published As
Publication number | Publication date |
---|---|
AU2004233775B2 (en) | 2009-10-22 |
AU2010200264A1 (en) | 2010-02-25 |
US20040229799A1 (en) | 2004-11-18 |
AU2004233775C1 (en) | 2010-03-18 |
US7834147B2 (en) | 2010-11-16 |
US20190192623A1 (en) | 2019-06-27 |
US20150125497A1 (en) | 2015-05-07 |
AU2004233775A1 (en) | 2004-11-11 |
JP2006524681A (en) | 2006-11-02 |
AU2010200264B2 (en) | 2013-02-14 |
EP1635856A4 (en) | 2011-04-06 |
CA2522833A1 (en) | 2004-11-11 |
BRPI0409926A (en) | 2006-04-25 |
CA2911022A1 (en) | 2004-11-11 |
WO2004096159A2 (en) | 2004-11-11 |
EP1635856A2 (en) | 2006-03-22 |
ES2828094T3 (en) | 2021-05-25 |
CA2522833C (en) | 2016-01-19 |
US20090269373A1 (en) | 2009-10-29 |
JP4762132B2 (en) | 2011-08-31 |
EP1635856B1 (en) | 2020-08-12 |
CA2911022C (en) | 2021-07-20 |
US8937156B2 (en) | 2015-01-20 |
US10188698B2 (en) | 2019-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004096159A3 (en) | Saposin c-dops: a novel anti-tumor agent | |
HUP0303976A2 (en) | Combination therapy using anti-egfr antibodies and hormone antagonists | |
SG166775A1 (en) | Combinations and modes of administration of therapeutic agents and combination therapy | |
WO2006053049A3 (en) | Herbal composition phy906 and its use in chemotherapy | |
WO2001066123A3 (en) | Composition consisting of phy906 and chemotherapeutic agents | |
TR200103560T2 (en) | Compositions for the diagnosis and treatment of breast cancer and their use | |
WO2003096990A3 (en) | Protein cages for the delivery of medical imaging and therapy | |
IL176007A0 (en) | Antibodies specific to c35 and pharmaceutical compositions containing the same | |
WO1999067284A3 (en) | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy | |
WO2006003488A3 (en) | Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof | |
WO2000055345A3 (en) | Therapy of cancer by insect cells containing recombinant baculovirus encoding genes | |
WO2002016413A3 (en) | Cripto tumour polypeptide | |
MXPA02000192A (en) | Compositions and methods for the therapy and diagnosis of lung cancer. | |
EA201200560A1 (en) | SPECIFIC THERAPY USING INTEGRINE LIGANDS FOR CANCER TREATMENT | |
HK1071310A1 (en) | Combination therapy for the treatment of cancer | |
WO2002092001A3 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
HUP0401903A2 (en) | Improved use of et-743 in cancer thereapy | |
IS6558A (en) | Mixed disease treatment with vasoconstrictor | |
WO2003037267A8 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
AU1206292A (en) | Therapeutic agents for the treatment of multidrug resistance to cancers | |
BR0311866A (en) | Saponin or sapogenin compositions for cancer therapy | |
WO2003017939A3 (en) | Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment | |
WO2005065361A3 (en) | Compounds and compositions for treating dysproliferative diseases, and methods of use thereof | |
WO2002053700A3 (en) | Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof | |
Marcu | Improving therapeutic ratio in head and neck cancer with adjuvant and cisplatin-based treatments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004801127X Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004760194 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2522833 Country of ref document: CA Ref document number: 2004233775 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006507237 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2004233775 Country of ref document: AU Date of ref document: 20040317 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004233775 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004760194 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0409926 Country of ref document: BR |